Articles

Editorial

Published on 02 August 2012

Generics policies–a globally-relevant implementation challenge

Abstract:  Vogler and Zimmerman, reporting on the 2011 Pharmaceutical Pricing and Reimbursement Information (PPRI) Conference, have noted the incomplete application of generics policies in many settings, and have called for...

Author(s): Andy Gray, MScPharm, FPS, FFIP

generics policies, transparency, WHO policy

DOI: 10.5639/gabij.2012.0103-4.027

26.533 views

Read more →

Letters to the Editor

Published on 11 October 2012

A clinician’s view of the ethics of the use of biosimilars

Abstract:  Comment on the Letters to the Editor by Dr Carlo Petrini: A bioethicist’s view of the use of biosimilars Submitted: 8 October 2012; Revised: 9 October 2012; Accepted: 9 October 2012;...

Author(s): Dr Kalle Hoppu

DOI: 10.5639/gabij.2012.0103-4.035

9.281 views

Read more →

Letters to the Editor

Published on 11 October 2012

A bioethicist’s view of the use of biosimilars

Abstract:  In recognition of the many ethically sensitive issues raised by the production and use of biosimilar medicinal products, the author imagines having to answer the non-multiple choice question ‘From...

Author(s): Carlo Petrini, PhD

bioethics, drugs, ethics committees, legislation, risk, safety

DOI: 10.5639/gabij.2012.0103-4.034

12.329 views

Read more →

Editor's Letter

Published on 14 November 2012

Latest features in GaBI Journal, 2012, issue 3-4

This issue of the GaBI Journal uses a number of article formats to cover a range of issues related to generics and biosimilars. In Letters to the Editor, Dr Carlo...

Author(s): Professor Philip D Walson, MD

DOI: 10.5639/gabij.2012.0103-4.037

10.618 views

Read more →

Abstracted Scientific Content

Published on 04 July 2012

Oncologists urged to embrace biosimilars to help control spiralling costs of cancer care

Oncologists urged to embrace biosimilars to help control spiralling costs of cancer care Oncologists have been urged to embrace biosimilar drug substitution to help control the spiralling costs of cancer care. However,...

Author(s): GaBI Journal Editor

DOI: 10.5639/gabij.2012.0102.022

7.811 views

Read more →

Guidelines

Published on 05 March 2012

Generics substitution in primary care: summary of the Dutch community pharmacies guidelines

Abstract:  Marketed medicines that have passed bioequivalence testing should in general be substitutable. However, for a variety of reasons, caution may be warranted, particularly with regard to narrow therapeutic index...

Author(s): Leonora Grandia, PharmD, Professor Arnold G Vulto, PharmD, PhD, FCP

biologicals, biosimilars, Dutch guidelines, generics substitution, interchangeability, narrow therapeutic index drugs

DOI: 10.5639/gabij.2012.0102.021

18.197 views

Read more →

Special Report

Published on 10 April 2012

The impact of pharmaceutical pricing and reimbursement policies on generics uptake: implementation of policy options on generics in 29 European countries─an overview

Introduction: To describe pharmaceutical pricing and reimbursement systems in 29 European countries with regard to medicines, particularly generics, and their possible impact on generics uptake. Method: Data collection on pharmaceutical pricing and...

Author(s): Sabine Vogler, PhD

generics policies, generics substitution, INN prescribing, pricing, reference pricing system, reimbursement

DOI: 10.5639/gabij.2012.0102.020

57.286 views

Read more →

Perspective

Published on 10 February 2012

Generic clopidogrel–the medicines agency’s perspective

Abstract:  A number of generic products containing clopidogrel as the active substance have been marketed in Austria and the EU for some time. Due to different clopidogrel salt preparations and different indications, doubts...

Author(s): Christoph Baumgärtel, MD, MSc

bioequivalence, clopidogrel, drug substitution, drugs, generics, therapeutic equivalence

DOI: 10.5639/gabij.2012.0102.019

37.322 views

Read more →

Perspective

Published on 08 May 2012

Promoting access to biosimilars: a public−private partnership model for biosimilar development in underserved populations

Author byline as per print journal: Timothy Ken Mackey1,2, MAS; Professor Bryan A Liang1,3,4, MD, JD, PhD Abstract:  Biologicals represent the future of pharmaceutical treatments and innovation. Yet, emerging and developing...

Author(s): Professor Bryan A Liang, MD, JD, PhD, Timothy Ken Mackey, MAS

biosimilars, emerging markets, follow-on biologics, global health, immunogenicity, patient safety, public−private partnerships

DOI: 10.5639/gabij.2012.0102.018

23.362 views

Read more →

Review Article

Published on 21 February 2012

Payers endorse generics to enhance prescribing efficiency: impact and future implications, a case history approach

Author byline as per print journal: Brian Godman1,2,3, BSc, PhD; Mohammed Abuelkhair4, PharmD; Agnes Vitry5, PharmD, PhD; Shajahan Abdu4, MD; Marion Bennie6,7, MSc; Iain Bishop7, BSc; Sahar Fahmy4, PhD; Kristina Garuoliene8,...

Author(s): Brian Godman, BSc, PhD, et al.

demand-side measures, generics, pharmaceuticals, pricing

DOI: 10.5639/gabij.2012.0102.017

36.687 views

Read more →

Review Article

Published on 05 March 2012

What lessons can be learned from the launch of generic clopidogrel?

Author byline as per print journal: Christoph Baumgärtel1, MD; Brian Godman2,3,4, BSc, PhD; Rickard E Malmstrom5, MD, PhD; Morten Andersen6, MD, PhD; Mohammed Abuelkhair7, PharmD; Shajahan Abdu7, MD; Marion Bennie8,9, MSc;...

Author(s): Christoph Baumgärtel, MD, MSc, et al.

clopidogrel, demand measures, generics, pricing

DOI: 10.5639/gabij.2012.0102.016

72.260 views

Read more →

Readers' Comments

Published on 01 August 2012

A patient-centred paradigm for the biosimilars market

A patient-centred paradigm for the biosimilars market This article provides important insights into the use and application of complex biologicals, particularly biosimilars, in health delivery systems. One aspect of care that has...

Author(s): GaBI Journal Editor

DOI: 10.5639/gabij.2012.0102.024

5.295 views

Read more →